Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP) and Nivolumab in Patients With Non-Metastatic, PSA-Recurrent Prostate Cancer

NCT03600350 is registered in ClinicalTrials.gov with University of Wisconsin, Madison as lead sponsor.

NCT NCT03600350
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03600350 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP) and Nivolumab in Patients With Non-Metastatic, PSA-Recurrent Prostate Cancer
Lead sponsor
University of Wisconsin, Madison
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 10, 2018
Completion date
December 31, 2027
Enrollment
19 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer